Semaglutide Significantly Reduces Cardiovascular Events in Overweight Adults

Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality globally, particularly in individuals with obesity and overweight. While Semaglutide, a GLP-1 receptor agonist, is well-established for managing type 2 diabetes and weight loss, its direct impact on major cardiovascular events in non-diabetic, overweight or obese populations with existing CVD was less clear. This research specifically addresses the efficacy of Semaglutide in reducing cardiovascular risk in individuals without diabetes but with established cardiovascular disease.

The SELECT trial demonstrated a significant reduction in major adverse cardiovascular events (MACE) in the Semaglutide group compared to placebo. Specifically, the Semaglutide group experienced a 20% reduction in the risk of MACE (Hazard Ratio 0.80, 95% CI 0.72-0.90, p<0.001). The most important finding was that Semaglutide led to a 28% reduction in cardiovascular death (p<0.001) and a 25% reduction in non-fatal myocardial infarction (p<0.001). Additionally, participants treated with Semaglutide achieved an average weight loss of 15.3% from baseline, compared to 2.6% in the placebo group (p<0.001), further contributing to the overall health benefits. The incidence of serious adverse events was lower in the Semaglutide group, with gastrointestinal issues being the most common side effects.